Quest Diagnostics Incorporated (NYSE:DGX) finished Friday with a subtraction of -$0.35 to close at $156.44, a downside of -0.22 percent. An average of 759,640 shares of common stock have been traded in the last five days. There was a gain of $0.81 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 1,058,805 shares traded, while the 50-day average volume stands at 1,157,478.
DGX stock has increased by 3.04% in the last month. The company shares reached their 1-month lowest point of $147.11 on 12/12/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $120.40 and a high of $174.16 in 52 weeks. It has reached a new high 1 time so far this year and lost -9.58% or -$16.57 in price. In spite of this, the price is down -10.17% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
DGX stock investors should be aware that Quest Diagnostics Incorporated (DGX) stock had its last reported insider trading activity 30 days ago on Dec 01. In this transaction, the insider spent $308,812. SVP, Regional Businesses, Doherty Catherine T., disposed of 40,765 shares at a price of $149.18 on Nov 28. The insider now owns more than $6,081,262 worth of shares. Prior to that, Director RING TIMOTHY M went on to Sale 2,000 shares at $144.06 each on Nov 01. An amount of $288,120 was transacted.
Quest Diagnostics Incorporated (DGX) has a trailing price-to-earnings (P/E) ratio of 15.42. The stock’s beta is 0.97. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.72, the price-to-book (PB) ratio at 2.91, and the price-to-cash flow ratio at 15.33.
The company has a payout ratio of 24.60%. The company’s most recent quarterly dividend payment was $0.66 a share, without any change from last year. Its latest increase dividend $0.04 reported on Thursday February 3 2022.
The quick ratio of Quest Diagnostics Incorporated for the three months ended September 29 was 1.30, and the current ratio was 1.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.64 and a total debt to equity ratio of 0.64 for the quarter ending September 29. Its gross profit as reported stood at $4.21 billion compared to revenue of $10.79 billion.
For the three-month period that ended September 29, Quest Diagnostics Incorporated had $3.98 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $256.0 million in the quarter, while revenues were shrunk -97.27%. The analyst consensus anticipated Quest Diagnostics Incorporated’s latest quarter earnings to come in at $2.19 per share, but it turned out to be $2.36, a 7.80% surprise. For the quarter, EBITDA amounted to $500.0 million. Shareholders own equity worth $113.89 million.
From a technical analysis perspective, let’s take a brief look at Quest Diagnostics Incorporated (DGX) price momentum. RSI 9-day as of the close on 30 December was 67.87%, suggesting the stock is Neutral, with historical volatility in this time frame at 18.19%.
As of today, DGX’s price is $156.67 +0.52% or $0.81 from its 5-day moving average. DGX is currently trading +2.51% higher than its 20-day SMA and +12.38% higher than its 100-day SMA. However, the stock’s current price level is +23.51% above the SMA50 and +9.18% above the SMA200.
The stochastic %K and %D were 84.37% and 87.43%, respectively, and the average true range (ATR) was 2.59. With the 14-day stochastic at 83.11% and the average true range at 2.78, the RSI (14) stands at 66.23%. The stock has reached 1.48 on the 9-day MACD Oscillator while the 14-day reading was at 3.42.
Citigroup downgraded Quest Diagnostics Incorporated (NYSE: DGX) to a a Sell rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Quest Diagnostics Incorporated (DGX) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell DGX, while 10 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 6 others rate it as a “buy”.
What is DGX’s price target for the next 12 months?
Analysts predict a range of price targets between $125.00 and $165.00, with a median target of $141.50. Taking a look at these predictions, the average price target given by analysts for Quest Diagnostics Incorporated (DGX) stock is $143.71.